4-(碘甲基)-5-甲基-2-苯基-1,3-恶唑 | 182187-60-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(碘甲基)-5-甲基-2-苯基-1,3-恶唑
• 中文别名: 噁唑,4-(碘甲基)-5-甲基-2-苯基-
• 英文名称: 4-iodomethyl-5-methyl-2-phenyloxazole
• 英文别名: 2-phenyl-4-iodomethyl-5-methyloxazole；4-(Iodomethyl)-5-methyl-2-phenyl-1,3-oxazole
• CAS: 182187-60-6
• 化学式: C₁₁H₁₀INO
• 分子量: 299.111
• InChiKey: MLRCAXSQHSXLRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl 2-(cis-3-hydroxycyclohexyloxymethyl)-6-methylbenzoate 、 4-(碘甲基)-5-甲基-2-苯基-1,3-恶唑 在 C26H29NO5 作用下， 以gave the product 69 of molecular weight 435.52 (C26H29NO5), MS(ESI)的产率得到2-methyl-6-[3-(5-methyl-2-phenyloxazol-4-yl-methoxy)cyclohexyloxymethyl]benzoic acid
  参考文献：
  名称：

  Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals

  摘要：

  本发明公开了二芳基环烷基衍生物及其生理上可接受的盐和生理上功能衍生物。这些化合物包括公式I中的基团所定义的那些基团及其生理上可接受的盐和制备它们的过程。这些化合物通常具有降脂和/或降三酰甘油的特性，例如，适用于治疗脂质代谢障碍，2型糖尿病和X综合症等疾病。

  公开号：

  US20050267177A1

文献信息

• Heterocyclic compounds
  申请人：——

  公开号：US20030166697A1

  公开（公告）日：2003-09-04

  The present invention provides a preventive or therapeutic agent for hyperlipidemia, comprising as an active ingredient a heterocyclic compound of the formula [1], or a pharmaceutically acceptable salt thereof: R 1 -Het-D-E  [1] wherein: R 1 is optionally substituted aryl or aromatic heterocyclic group, Het is a divalent aromatic heterocyclic group, D is alkylene, alkenylene, alkynylene, or the like, and E is carboxy, or the like, and novel compounds among the heterocyclic compounds of the formula [1] above, which has blood triglyceride lowering effect, LDL-C lowering effect, and blood glucose lowering effect and blood insulin lowering effect, or HDL-C increasing effect or atherogenic index lowering effect all together, and hence is useful in the prevention or treatment of hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity, and the like.

  本发明提供了一种用于高脂血症的预防或治疗剂，其活性成分为式[1]所示的杂环化合物或其药学上可接受的盐：R1-Het-D-E [1]其中：R1为任选取代的芳基或芳香性杂环基团，Het为二价芳香性杂环基团，D为亚烷基、亚烯基、亚炔基等，E为羧基等，以及上述式[1]所示杂环化合物中的新型化合物，其具有降低血液甘油三酯、降低LDL-C、降低血糖、降低血液胰岛素、增加HDL-C或降低动脉粥样硬化指数的效果，因此可用于预防或治疗高脂血症、动脉硬化、糖尿病、高血压、肥胖等疾病。
• Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals
  申请人：——

  公开号：US20030144332A1

  公开（公告）日：2003-07-31

  Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.

  披萨店的员工们正在忙着准备今晚的外卖订单。
• Propionic acid derivatives
  申请人：——

  公开号：US20020032330A1

  公开（公告）日：2002-03-14

  A propionic acid derivative having the following formula (II) and its salt: 1 [wherein A 1 is an aryl or heterocyclic group which may have a substituent; Y 2 is an alkylene chain having 1 to 5 carbon atoms; X 4 is a single bond, an oxygen atom, or a sulfur atom; W 1 is a naphthalene ring, a quinoline ring, an indole ring, a benzisoxazole ring, or benzo[b]thiophene ring, all of which may have a substituent; R 4 is a hydrogen atom or an alkyl group having 1 to 8 carbon atoms; X 5 is an oxygen atom or a sulfur atom; R 5 is an alkyl group having 1 to 8 carbon atoms, an aralkyl group, or an aryl group, all of which may have a substituent] have a hypoglycemic effect and hypolipidemic activity.

  具有以下结构式（II）及其盐的丙酸衍生物：其中A1为可能具有取代基的芳基或杂环基；Y2为具有1至5个碳原子的烷基链；X4为单键、氧原子或硫原子；W1为萘环、喹啉环、吲哚环、苯并异噁唑环或苯并噻吩环，均可能具有取代基；R4为氢原子或具有1至8个碳原子的烷基基团；X5为氧原子或硫原子；R5为具有1至8个碳原子的烷基基团、芳基烷基基团或芳基，均可能具有取代基，具有降血糖作用和降脂活性。
• Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040209920A1

  公开（公告）日：2004-10-21

  Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders and also disorders in which insulin resistance is involved.

  芳基环烷基取代的烷基酸衍生物，其制备方法及其作为药物的用途。该发明涉及芳基环烷基取代的烷基酸衍生物及其生理可接受的盐和生理功能衍生物。所描述的化合物为式I，其中基团如所定义，以及其生理可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢障碍、葡萄糖利用障碍以及胰岛素抵抗相关的疾病。
• ARYLYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：Stapper Christian

  公开号：US20080167354A1

  公开（公告）日：2008-07-10

  The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders and also disorders in which insulin resistance is involved.

  该发明涉及芳基环烷基取代的脂肪酸衍生物及其生理上可接受的盐和生理功能衍生物。所描述的是公式I中的化合物，其中基团如定义的那样，以及它们的生理上可接受的盐和制备它们的过程。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗有关的疾病。